T. Rowe Price Investment Management, Inc. Nurix Therapeutics, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $151 Billion
- Q1 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 2,428,283 shares of NRIX stock, worth $29.5 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
2,428,283
Previous 2,380,428
2.01%
Holding current value
$29.5 Million
Previous $44.8 Million
35.67%
% of portfolio
0.02%
Previous 0.03%
Shares
6 transactions
Others Institutions Holding NRIX
# of Institutions
181Shares Held
74.4MCall Options Held
56.9KPut Options Held
7.9K-
Black Rock Inc. New York, NY6.82MShares$82.8 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.5MShares$66.8 Million2.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$53.6 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.05MShares$49.2 Million5.06% of portfolio
-
Commodore Capital LP New York, NY3.98MShares$48.3 Million4.63% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $572M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...